You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and MSD have announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologouAlready a subscriber Login You have read all your free…
Novo Nordisk and Glooko announces that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk's knowledge of diabetes with Glooko's digital platform and data analytiAlready a subscriber Login You have read all your free…
AstraZeneca has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with an irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACPAlready a subscriber Login You have read all your free…
AstraZeneca and Merck & Co have announced that the European Medicines Agency has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). “There is no cure for NF1, a life-long and devastating condition, and current treatment choicAlready a subscriber Login You have…
